177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

Trial Details

NCT ID

NCT07189871

Phase

PHASE1 / PHASE2

Sponsor

Radiopharm Theranostics, Ltd

Status

RECRUITING

Cancer Type

Uterine Cancer

Interventions

• 177Lu-BetaBart

Locations (sample)

• Dothan, Alabama, United States|31.22323,-85.39049
• Grand Rapids, Michigan, United States|42.96336,-85.66809
• Omaha, Nebraska, United States|41.25626,-95.94043
• Omaha, Nebraska, United States|41.25626,-95.94043
• Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

• Participants ≥ 18 years of age.
• Participants with a documented history of histopathologically confirmed CRPC\*, CRC, NSCLC, SCLC, HNSCC, ovarian cancer, cervical cancer, endometri…
• a. \*Progressive CRPC defined by at least one of the following criteria: i. Two consecutive increases in PSA measured at least 1 week apart. ii. So…
• iii. Progression of bone disease defined by Prostate Cancer Working Group 3 (PCWG3) as evaluable disease or new bone lesions by bone scan.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.